CYTO Message Board - Msg: 13388472

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO

CYTO 0.300

0.0%

Dec 19 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bill Ounce who wrote (7846)	4/10/2000 12:50:00 PM
From: Jim Oravetz	Read Replies (2) of 8116

Cytogen Corp. (CYTO) received a proteomics patent from the Japanese Patent Office for its "Totally Synthetic Affinity Reagents" technology. The technology, which is covered by a U.S. patent, is a method of identifying ligands or portions of proteins, that interact with receptors, protein domains, antibodies or nucleic acids. In a press release Monday, Cytogen said its AxCell Biosciences Corp. unit is using the process to generate information about protein interactions for its Inter-functional Proteomic Database of protein signaling pathways. AxCell plans to use the database for the discovery of new drug targets. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next